Litcius/Paper detail

Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis

Nicola Capasso, Agostino Nozzolillo, Giulia Scalia, Roberta Lanzillo, Antonio Carotenuto, Marcello De Angelis, Martina Petruzzo, Francesco Saccà, Cinzia Valeria Russo, Vincenzo Brescia Morra, Marcello Moccia

2021Multiple Sclerosis and Related Disorders37 citationsDOI

Topics & Concepts

OcrelizumabMedicineRituximabMultiple sclerosisCD20CD8CD19ImmunologyLymphocyteInternal medicineFlow cytometryAntibodyAntigenMultiple Sclerosis Research StudiesImmunotherapy and Immune ResponsesPolyomavirus and related diseases
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis | Litcius